Supported by a significant track record in this area, the PMC is at the forefront of modern Hybridization pathology, digital pathology and artificial intelligence applied to tissues and cells
"After the ‘molecular revolution’, the introduction of artificial intelligence in diagnostic and therapeutic medicine represents a new frontier, and digital pathology (DP) is one of its most obvious applications. Our PMC has experience in helping industry to bring new DP diagnostic algorithms to the market and, together with our capacity in genomic medicine, represents an unparalleled opportunity to engage in true, integrated analyses to support industry product development, clinical trial endeavours and programmatic research."
Professor Manuel Salto-Tellez, Tissue Hybridisation & Digital Pathology Lead
Dr Jackie James, Tissue Hybridization and Digital Pathology Lead
Supported by a significant track record in this area, the PMC is at the forefront of modern hybridization pathology, digital pathology and artificial intelligence applied to tissues and cells. Since 2011, the Belfast Digital Pathology (DP) Programme (Salto-Tellez, James and Hamilton)  has a) received substantial funding (€3.9m EU Framework, £3.7m CRUK Accelerator on DP and £3.5M from Innovate UK on artificial intelligence); b) developed the most successful DP open source system to date (QuPath) ; c) created the first DP prototype of tissue annotation ahead of molecular testing, TissueMark ; d) generated important validation information on DP scoring of biomarkers [2, 4]; and e) successfully applied DP to novel biomarkers of difficult clinical delivery such as PD-L1 .
1. Hamilton PW, James J, Salto-Tellez M et al. Methods. 2014 Nov;70(1):59-73.
2. Bankhead P, James JA, Salto-Tellez M, Hamilton PW et al. Sci Rep. 2017 Dec 4;7(1):16878.
3. Hamilton PW, James JA, Salto-Tellez M et al. Oncotarget 2015 Sep 29;6(29):27938-52
4. Bankhead P, James JA, Salto-Tellez M, Hamilton PW Lab Invest. 2018 Jan;98(1):15-26
5. Humphries M et al (James JA and Salto-Tellez M). J Thorac Oncol. 2019 Jan;14(1):45-53.